Clinical Trial: Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07761286) titled 'Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma' on July 30.

Brief Summary: This is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: HCC - Hepatocellular Carcinoma

Intervention: DRUG: SYS6090 Injection + Bevacizumab Injection

SYS6090 in Combination with Bevacizumab 15mg/kg

DRUG: SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection

SY...